Critical appraisal of lurasidone in the management of schizophrenia.

Neuropsychiatric Disease and Treatment
Silvio CacciaAlessandro Nobili

Abstract

Lurasidone is a new atypical antipsychotic in the benzoisothiazoles class of chemicals. Like most second-generation antipsychotics it is a full antagonist at dopamine D(2) and serotonin 5-HT(2A) receptors, and is a partial agonist at 5-HT(1A) receptors, a property shared by some but not all older agents. It has much greater affinity for 5-HT(7) subtype receptors than other atypical antipsychotics. Pharmacokinetic studies showed that lurasidone is reasonably rapidly absorbed, with bioavailability appearing to be increased by food. Lurasidone undergoes extensive metabolism to a number of metabolites, some of which retain pharmacological activities. Metabolism is mainly by CYP3A4, resulting in steady-state concentrations that vary between individuals and are potentially affected by strong inducers and inhibitors of this enzyme. Short-term clinical trials have demonstrated the efficacy of lurasidone in acute schizophrenia, with doses of 40 and 80 mg/day giving significant improvements from baseline in the PANSS and BPRS scores. The most common adverse events are nausea, vomiting, akathisia, dizziness, and sedation, with minimal increases in the risk of developing metabolic syndrome. Lurasidone did not raise the risk of QTc interval...Continue Reading

References

Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·H Y Meltzer
Aug 3, 2002·CNS Drugs·Nishan S GunasekaraGillian M Keating
Mar 12, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Wesley K KroezeBryan L Roth
Jan 28, 2004·The Journal of Clinical Psychiatry·Stephen M Stahl
Jun 1, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wulf RösslerAnita Riecher-Rössler
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Sep 29, 2005·The Journal of Clinical Psychiatry·Eric Q WuJyoti Aggarwal
Nov 11, 2005·Journal of Psychopharmacology·Peter Haddad
Mar 15, 2006·CNS Drugs·David Murdoch, Gillian M Keating
May 11, 2006·Psychosomatics·Thomas W HeinrichJohn Schneider
Aug 24, 2006·Expert Opinion on Pharmacotherapy·Barrat Luft, David Taylor
Feb 3, 2007·Expert Opinion on Drug Metabolism & Toxicology·Pedro DoradoAdrián Llerena
Feb 17, 2007·Medical Hypotheses·Mary V Seeman
Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Aug 21, 2009·The International Journal of Neuropsychopharmacology·Antonio MantovaniSarah H Lisanby
Sep 29, 2009·Expert Opinion on Investigational Drugs·Jonathan M MeyerEdward Schweizer
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)
Apr 7, 2010·Drug Design, Development and Therapy·Silvio CacciaAlessandro Nobili
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Dec 24, 2010·Clinical Schizophrenia & Related Psychoses·Leslie Citrome
Mar 23, 2011·Current Opinion in Pharmacology·H Y Meltzer, B W Massey
Apr 12, 2011·Expert Opinion on Drug Metabolism & Toxicology·Silvio Caccia
May 12, 2011·The Journal of Pharmacology and Experimental Therapeutics·M HoriguchiH Y Meltzer
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Jul 15, 2011·Therapeutics and Clinical Risk Management·Ludovic SamalinPierre-Michel Llorca

❮ Previous
Next ❯

Citations

May 2, 2014·Expert Review of Neurotherapeutics·Cecilio AlamoPilar García-García
Jan 31, 2015·Expert Opinion on Investigational Drugs·Mauro Giovanni CartaJoseph R Calabrese
Jan 19, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Konstantinos N FountoulakisHagop Akiskal
May 21, 2016·Pharmacological Reports : PR·Rafał R JaeschkeWojciech Datka
Jun 28, 2016·Expert Opinion on Drug Safety·L OrsoliniD De Berardis
Jul 15, 2015·Chemical Society Reviews·Tegan P Stockdale, Craig M Williams
Jun 20, 2018·Clinical Pharmacokinetics·Massimo Carlo MauriAlfredo Carlo Altamura
Aug 16, 2018·MedChemComm·Maria AzmanovaNicolas P E Barry
May 25, 2021·Therapeutic Advances in Psychopharmacology·Marco Andrea RivaDomenico De Berardis

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Therapeutics and Clinical Risk Management
Ludovic SamalinPierre-Michel Llorca
Expert Review of Neurotherapeutics
Joshua T Kantrowitz, Leslie Citrome
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists
David R P Guay
Issues in Mental Health Nursing
Shambria F Nolan, Marian W Roman
© 2021 Meta ULC. All rights reserved